Harrow, Inc. announced its first major market access wins for VEVYE (cyclosporine ophthalmic solution) 0.1% within the 2025 Medicare Part D Prescription Drug Program. Starting January 1, 2025, VEVYE will be included in key formularies managed by major plan sponsors such as Express Scripts, Cigna, Kaiser Permanente, and CVS Caremark.
These plan sponsors collectively represent over 25 million Medicare Part D beneficiaries, significantly expanding VEVYE's reach. In addition to Medicare Part D, VEVYE has achieved broad coverage across other major insurance programs, including 100% of U.S. Medicaid programs and 60% of commercial insurance coverage. This broad access is critical for treating chronic dry eye disease, which affects millions of Americans, particularly older adults.
Mark L. Baum, Chairman and CEO of Harrow, stated that Medicare access is essential for VEVYE's continued success as a preferred dry eye disease treatment. The expanded access aims to serve Medicare beneficiaries by improving their eye health, independence, and quality of life, addressing a substantial need for effective and tolerable dry eye treatments among the 67 million Medicare beneficiaries in the U.S.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.